The S-thiophenyl-masked cysteine is introduced into a fully automated microwave-assisted solid-phase peptide synthesis campaign for a disulfide-cyclized peptide drug substance. The resin is Rink amide MBHA with a substitution of 0.42 mmol/g; the amino acid derivative is dissolved in DMF to 0.2 mol/L and charged at 1.05 molar equivalents per free amine after Fmoc removal with 20% v/v piperidine/DMF. Coupling is run at 50°C ± 2°C for 30 min with HBTU and DIPEA; an automatic second coupling is triggered when the Kaiser test shows residual free amine above 0.1% of resin sites. After linear assembly, the peptide is cleaved with TFA/TIS/H₂O 95:2.5:2.5 v/v/v at 25°C ± 2°C for 2.5 h, precipitated in cold methyl tert-butyl ether at -20°C, and washed twice. Disulfide formation is performed in 0.1 M ammonium bicarbonate buffer at pH 8.0 ± 0.1 with 1 mM EDTA for 12 h; free thiol is monitored by Ellman’s assay until ≤ 0.2 mol thiol per mole of peptide is reached. The crude cyclic peptide is purified on a 10 cm C18 preparative column using 0.1% v/v TFA in an acetonitrile/water gradient and lyophilized at -40°C shelf temperature and 0.08 mbar for 48 h.

The resulting peptide API is tested under ICH Q7 Section 12.4 and 21 CFR 210/211, with quality attributes aligned to USP <1503>; release includes chromatographic purity by Ph. Eur. 2.2.29, residual TFA by ion chromatography, and water content by USP <921> Karl Fischer. Terminal product types are lyophilized acetate salts of disulfide-bridged cyclic peptide drug substances, including somatostatin, vasopressin and oxytocin receptor ligand analogues.

What Limits Residual Solvent Control in Solution-Phase Fragment Coupling at 50 L?

In solution-phase production of a C-terminal cysteine-containing fragment, N-Cbz-S-thiophenyl-L-cysteine is used as an N-protected building block that prevents diketopiperazine formation during activation. The coupling is carried out in a 50 L glass-lined reactor equipped with a turbofoil impeller at 90 rpm. The carboxyl fragment is dissolved in THF/DMF 4:1 v/v and cooled to -12°C ± 2°C; isobutyl chloroformate is added at 1.05 equivalents relative to the carboxyl component and N-methylmorpholine at 1.20 equivalents. After 10 min activation, N-Cbz-S-thiophenyl-L-cysteine is charged at 1.10 equivalents relative to the carboxyl component. The reaction is quenched with 5% w/v aqueous citric acid, washed with 7% w/v sodium bicarbonate and 15% w/v sodium chloride, and dried over magnesium sulfate. The product is crystallized from ethyl acetate/n-heptane 1:3 v/v at -20°C for 16 h.

The main production-scale failure mode is incomplete scavenging of isobutyl chloroformate, which forms a carbamate impurity if the mixed anhydride is quenched too early; in-process control is therefore performed by TLC after the 10 min activation window and before addition of the cysteine derivative. Process validation follows ICH Q11; release testing uses Ph. Eur. 2.2.29 for related substances, chiral HPLC for enantiomeric purity, and USP <467> for tetrahydrofuran at ≤ 720 ppm and n-heptane at ≤ 5000 ppm. The terminal product is a protected peptide fragment of 5–30 residues that is used in convergent synthesis of larger peptide drug substances.

At 20 mmol scale, cosmetic peptide active synthesis using the S-thiophenyl-protected cysteine is carried out in a 500 mL jacketed reactor with overhead stirring at 200 rpm. The building block is charged at 1.00 equivalent relative to an amine-terminated peptide fragment and activated with DIC/HOBt in DMF at 0°C ± 2°C; coupling reaches a negative Kaiser test at 45 min. The N-Cbz group is removed by hydrogenolysis over 10% w/w Pd/C at 0.3 MPa hydrogen pressure in methanol/water 9:1 v/v for 6 h; the S-thiophenyl group is maintained through purification to suppress premature thiol oxidation. Purification uses a C18 preparative HPLC column with 0.1% v/v TFA in an acetonitrile/water gradient; the collected fraction is lyophilized at -45°C and 0.08 mbar for 72 h. The resulting peptide active is a lyophilized powder for final cosmetic formulation at 0.01–0.10 wt% in a serum or cream.

Facility compliance follows ISO 22716:2007, while the finished cosmetic product is assessed under Regulation (EC) No 1223/2009. Residual palladium is measured by ICP-MS per ICH Q3D with a limit of ≤ 10 ppm; residual methanol and DMF are controlled per USP <467>. The terminal products are cosmetic peptide active powders containing disulfide-bridged cysteine residues for skin care formulations.

Custom Peptide CDMO Campaigns Using Single-Shot Fritted Vessel Synthesis

For custom peptide CDMO campaigns, the derivative is handled in manual single-shot fritted polypropylene vessels at 0.25 mmol resin substitution because prolonged preactivation leads to aggregation. The coupling solution is prepared at 0.15 mol/L in DMF with HATU and 2,4,6-collidine; the derivative is charged at 2.0 equivalents per coupling and delivered as two sequential 45 min couplings at 25°C ± 1°C. Deprotection uses 20% v/v piperidine/DMF for 2 × 3 min. Kaiser test is performed after each coupling; a second coupling is discharged only when the resin beads remain blue. Cleavage uses TFA/TIS/H₂O 95:2.5:2.5 v/v/v for 2 h, followed by precipitation in cold diethyl ether at -20°C. The crude product is purified on a C18 semipreparative HPLC column and lyophilized at -40°C for 48 h.

Batch-to-batch variance in manual coupling arises from resin swelling differences in the fritted vessel; pre-swelling in DMF for 30 min at 25°C is mandatory before initiating the first coupling cycle. Published data for the exact coupling kinetics of N-Cbz-S-thiophenyl-L-cysteine under single-shot fritted vessel conditions is limited; the stated parameters derive from process development reports for structurally analogous protected cysteine derivatives and should be confirmed by reactor-specific DOE. Release is conducted under ISO 9001:2015 and USP <621>; residual TFA is limited to ≤ 1.0% w/w by ion chromatography. The terminal products are research-grade custom peptides of 5–50 residues for receptor-binding assays, immunogenicity testing, and assay development.

When the S-Thiophenyl Group Is Retained as a Masking Synthon During Preparation of Reference Standards

Reference standard manufacturers prepare peptide impurity markers from N-Cbz-S-thiophenyl-L-cysteine at 0.5 mmol scale in a 10 mL round-bottom flask. The derivative is coupled at 1.0 equivalent to a protected peptide fragment using EDC/HOBt in dichloromethane/DMF 3:1 v/v at 0°C ± 2°C. The Cbz group is removed by transfer hydrogenation with ammonium formate over 5% w/w Pd/C in methanol/water 4:1 v/v at 40°C ± 2°C for 4 h; the thiophenyl group is retained as a stable thioether handle throughout purification. Semipreparative C18 HPLC with 0.1% v/v TFA and acetonitrile yields the impurity marker; qNMR against a maleic acid certified reference material gives an absolute purity of ≥ 95.0% w/w. The manufacturer conducts release under ISO 17034:2016 and ISO/IEC 17025:2017; certificates include traceability statements, storage conditions at -20°C ± 2°C, and retest intervals. The terminal products are certified peptide impurity markers and system suitability mixtures used for pharmacopoeial method verification.

In diagnostic substrate manufacturing, the S-thiophenyl-masked cysteine is used as a C-terminal residue in fluorogenic peptide substrates for protease activity assays. A 5 mmol batch is assembled by solution-phase coupling of the protected cysteine derivative to a chromophore-amine conjugate at a charge ratio of 1.2 equivalents; HATU/DIPEA is used in DMF at 25°C ± 1°C for 60 min. The N-Cbz group is removed by catalytic hydrogenation at 0.2 MPa over 5% w/w Pd/C in methanol/water 4:1 v/v; the thiophenyl group is retained to avoid side reactions with maleimide-containing assay components. The crude substrate is purified by preparative HPLC with 0.1% v/v acetic acid in an acetonitrile/water gradient; fractions are lyophilized at -40°C and 0.05 mbar for 60 h. Release under ISO 13485:2016 includes identity by LC-MS, purity by USP <621>, and residual DMF by USP <467> with a limit of ≤ 880 ppm. Terminal products are lyophilized fluorogenic peptide substrates used in 96-well and 384-well protease assay kits.